Llwytho...
Initial Testing (Stage 1) of MK-8242, a Novel MDM2 Inhibitor, by the Pediatric Preclinical Testing Program
BACKGROUND: MK-8242 is an inhibitor of MDM2 that stabilizes the tumor suppressor TP53 and induces growth arrest or apoptosis downstream of TP53 induction. PROCEDURES: MK-8242 was tested against the PPTP in vitro cell line panel at concentrations from 1.0 nM to 10.0 μM and against the PPTP in vivo xe...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Pediatr Blood Cancer |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5657425/ https://ncbi.nlm.nih.gov/pubmed/27238606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26064 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|